November 2019 - When will the TECENTRIQ patents expire, and when will biosimilar TECENTRIQ launch?

Sponsor	Phase
Roche Pharma AG	Phase 4
Chonnam National University Hospital	Phase 4
Rutgers, The State University of New Jersey	Phase 1

Sponsor

Phase

Roche Pharma AG

Phase 4

Chonnam National University Hospital

Phase 4

Rutgers, The State University of New Jersey

Phase 1

These patents were identified by searching patent claims

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Estimated Patent Expiration	Status	Orphan	Source
Genentech Inc	TECENTRIQ	atezolizumab	INJECTABLE;INJECTION	761034	001	2017-04-17	Start Trial	Celgene Corporation (Summit, NJ) The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC)	2035-06-26	RX		search
Genentech Inc	TECENTRIQ	atezolizumab	INJECTABLE;INJECTION	761034	001	2017-04-17	Start Trial	ModernaTX, Inc. (Cambridge, MA)	2035-12-23	RX		search
Genentech Inc	TECENTRIQ	atezolizumab	INJECTABLE;INJECTION	761034	001	2017-04-17	Start Trial	ModernaTX, Inc. (Cambridge, MA)	2036-05-18	RX		search
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Number	>Approval Date	>Patent No.	>Assignee	>Estimated Patent Expiration	>Status	>Orphan	>Source

Country

Patent Number

Estimated Expiration

>Country

>Patent Number

>Estimated Expiration

Patents:	29
Applicants:	1
BLAs:	2
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for TECENTRIQ

Ingredient-type	Antibodies, Monoclonal, Humanized Antibodies, Monoclonal Antibodies
Mechanism of Action	Programmed Death Receptor-1-directed Antibody Interactions

TECENTRIQ Drug Profile